קלרידקס

Nazione: Israele

Lingua: ebraico

Fonte: Ministry of Health

Principio attivo:

CLARITHROMYCIN

Commercializzato da:

DEXCEL LTD, ISRAEL

Codice ATC:

J01FA09

Forma farmaceutica:

קפליות

Composizione:

CLARITHROMYCIN 250 MG

Via di somministrazione:

פומי

Tipo di ricetta:

מרשם נדרש

Prodotto da:

DEXCEL LTD, ISRAEL

Gruppo terapeutico:

CLARITHROMYCIN

Area terapeutica:

CLARITHROMYCIN

Indicazioni terapeutiche:

Klaridex is indicated in the treatment of infections caused by one or more susceptible organisms. Indications include: Lower respiratory tract infections, for example, acute and chronic bronchitis and pneumonia. Upper respiratory tract infections, for example, sinusitis and pharyngitis. Klaridex is appropriate for initial therapy in community acquired respiratory infections and has been shown to be active in vitro against common and atypical respiratory pathogens as listed in the microbiology section. Klaridex is also indicated in skin and soft tissue infections of mild to moderate severity. Klaridex is also indicated in combination with proton pump inhibitor for the eradication of H. Pylori in patients with proven duodenal ulcer. Treatment of Mycobacterium Avium Complex infection in AIDS patients.

Data dell'autorizzazione:

2014-05-31